Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors

Guardado en:

Detalles Bibliográficos
Autores principales:	Jia Chen, Yu-Chao Zhu, Hany M Elsheikha, Jian-Hua Wang, Shuai Fang, Jun-Jun He, Xing-Quan Zhu
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/3154ce45d4f44467bc3c77641cdf324d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3154ce45d4f44467bc3c77641cdf324d
record_format	dspace
spelling	oai:doaj.org-article:3154ce45d4f44467bc3c77641cdf324d2021-12-05T09:00:06ZSynergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors10.1136/jitc-2021-0029702051-1426https://doaj.org/article/3154ce45d4f44467bc3c77641cdf324d2021-11-01T00:00:00Zhttps://jitc.bmj.com/content/9/11/e002970.fullhttps://doaj.org/toc/2051-1426Jia ChenYu-Chao ZhuHany M ElsheikhaJian-Hua WangShuai FangJun-Jun HeXing-Quan ZhuBMJ Publishing GrouparticleNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJournal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Jia Chen Yu-Chao Zhu Hany M Elsheikha Jian-Hua Wang Shuai Fang Jun-Jun He Xing-Quan Zhu Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
format	article
author	Jia Chen Yu-Chao Zhu Hany M Elsheikha Jian-Hua Wang Shuai Fang Jun-Jun He Xing-Quan Zhu
author_facet	Jia Chen Yu-Chao Zhu Hany M Elsheikha Jian-Hua Wang Shuai Fang Jun-Jun He Xing-Quan Zhu
author_sort	Jia Chen
title	Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
title_short	Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
title_full	Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
title_fullStr	Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
title_full_unstemmed	Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors
title_sort	synergy between toxoplasma gondii type i δgra17 immunotherapy and pd-l1 checkpoint inhibition triggers the regression of targeted and distal tumors
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/3154ce45d4f44467bc3c77641cdf324d
work_keys_str_mv	AT jiachen synergybetweentoxoplasmagondiitypeidgra17immunotherapyandpdl1checkpointinhibitiontriggerstheregressionoftargetedanddistaltumors AT yuchaozhu synergybetweentoxoplasmagondiitypeidgra17immunotherapyandpdl1checkpointinhibitiontriggerstheregressionoftargetedanddistaltumors AT hanymelsheikha synergybetweentoxoplasmagondiitypeidgra17immunotherapyandpdl1checkpointinhibitiontriggerstheregressionoftargetedanddistaltumors AT jianhuawang synergybetweentoxoplasmagondiitypeidgra17immunotherapyandpdl1checkpointinhibitiontriggerstheregressionoftargetedanddistaltumors AT shuaifang synergybetweentoxoplasmagondiitypeidgra17immunotherapyandpdl1checkpointinhibitiontriggerstheregressionoftargetedanddistaltumors AT junjunhe synergybetweentoxoplasmagondiitypeidgra17immunotherapyandpdl1checkpointinhibitiontriggerstheregressionoftargetedanddistaltumors AT xingquanzhu synergybetweentoxoplasmagondiitypeidgra17immunotherapyandpdl1checkpointinhibitiontriggerstheregressionoftargetedanddistaltumors
_version_	1718372546707980288

Synergy between Toxoplasma gondii type I ΔGRA17 immunotherapy and PD-L1 checkpoint inhibition triggers the regression of targeted and distal tumors

Ejemplares similares